{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:06:00Z","timestamp":1782633960842,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.rmed.2025.108301","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T16:01:29Z","timestamp":1754582489000},"page":"108301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Management of anti-drug antibodies against TNF-inhibitors in sarcoidosis patients"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0882-2832","authenticated-orcid":false,"given":"Brady","family":"Otten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3749-4572","authenticated-orcid":false,"given":"Danielle","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew J.","family":"Gregoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4944-1627","authenticated-orcid":false,"given":"W. Ennis","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rmed.2025.108301_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12016-014-8450-y","article-title":"The clinical features of sarcoidosis: a comprehensive review","volume":"49","author":"Judson","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"6","key":"10.1016\/j.rmed.2025.108301_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2025.108301_bib3","first-page":"280","article-title":"The indications for the treatment of sarcoidosis: Wells Law. Sarcoidosis Vasc diffuse lung","volume":"34","author":"Baughman","year":"2017","journal-title":"Dis"},{"issue":"1","key":"10.1016\/j.rmed.2025.108301_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.rdc.2015.08.012","article-title":"Corticosteroids in sarcoidosis","volume":"42","author":"Judson","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"issue":"1","key":"10.1016\/j.rmed.2025.108301_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e3181b97635","article-title":"Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations","volume":"339","author":"McKinzie","year":"2010","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.rmed.2025.108301_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.108301_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108301_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106081","article-title":"Corticosteroid refractory sarcoidosis","volume":"171","author":"Goldman","year":"2020","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108301_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12931-022-01971-5","article-title":"Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis","volume":"23","author":"Sakkat","year":"2022","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.rmed.2025.108301_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.rmed.2013.11.019","article-title":"The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial","volume":"108","author":"Judson","year":"2014","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108301_bib11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000328738","article-title":"Long-term treatment with infliximab in patients with sarcoidosis","volume":"83","author":"Hostettler","year":"2012","journal-title":"Respiration"},{"issue":"7","key":"10.1016\/j.rmed.2025.108301_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108301_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2025.108301_bib14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","article-title":"Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients","volume":"47","author":"Jamilloux","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.rmed.2025.108301_bib15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2012","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"1","key":"10.1016\/j.rmed.2025.108301_bib16","first-page":"46","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"5","key":"10.1016\/j.rmed.2025.108301_bib17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","article-title":"A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis","volume":"68","author":"Pariser","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.rmed.2025.108301_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/flgastro-2014-100527","article-title":"Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide","volume":"7","author":"Hendy","year":"2016","journal-title":"Frontline Gastroenterol."},{"issue":"4","key":"10.1016\/j.rmed.2025.108301_bib19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.rmed.2025.108301_bib20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/00365521.2010.536254","article-title":"Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease","volume":"46","author":"Steenholdt","year":"2011","journal-title":"Scand. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.rmed.2025.108301_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.rmed.2025.108301_bib22","doi-asserted-by":"crossref","DOI":"10.1186\/ar3386","article-title":"Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases","volume":"13","author":"Ducourau","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.rmed.2025.108301_bib23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.108301_bib24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.rmed.2025.108301_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FTD.0b013e318180e300","article-title":"Infliximab pharmacokinetics in inflammatory bowel disease patients","volume":"30","author":"Ternant","year":"2008","journal-title":"Ther. Drug Monit."},{"issue":"11","key":"10.1016\/j.rmed.2025.108301_bib26","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl 3","key":"10.1016\/j.rmed.2025.108301_bib27","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.rmed.2025.108301_bib28","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.rmed.2025.108301_bib29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"issue":"8","key":"10.1016\/j.rmed.2025.108301_bib30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.rmed.2025.108301_bib31","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American thoracic society\/european respiratory society\/world association of sarcoidosis and other granulomatous disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"5","key":"10.1016\/j.rmed.2025.108301_bib32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MCP.0000000000000596","article-title":"The diagnosis of sarcoidosis","volume":"25","author":"Judson","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"8","key":"10.1016\/j.rmed.2025.108301_bib33","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An official American thoracic society clinical practice guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108301_bib34","first-page":"19","article-title":"The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.rmed.2025.108301_bib35","unstructured":"!!! INVALID CITATION !!! [29]."},{"issue":"11\u201312","key":"10.1016\/j.rmed.2025.108301_bib36","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.rmed.2025.108301_bib37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.rmed.2025.108301_bib38","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.rmed.2025.108301_bib39","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"15","key":"10.1016\/j.rmed.2025.108301_bib40","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108301_bib41","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.rmed.2025.108301_bib42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.rmed.2025.108301_bib43","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.rmed.2025.108301_bib44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.42335","article-title":"A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings","volume":"75","author":"Botson","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.rmed.2025.108301_bib45","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40262-015-0361-4","article-title":"Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics","volume":"55","author":"Gill","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.rmed.2025.108301_bib46","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125003646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125003646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:52:38Z","timestamp":1767714758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125003646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":46,"alternative-id":["S0954611125003646"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108301","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of anti-drug antibodies against TNF-inhibitors in sarcoidosis patients","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108301"}}